Preclinical analyses and phase I evaluation of LY2603618 administered in combination with Pemetrexed and cisplatin in patients with advanced cancer

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Investigational new drugs

• Publication date

  2014-06-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10637-014-0114-5PMID 24942404
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor

  2014cited by this paper
• Chk1/2 Inhibition Overcomes the Cisplatin Resistance of Head and Neck Cancer Cells Secondary to the Loss of Functional p53

  2013cited by this paper
• Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer

  2013cited by this paper
• Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.

  2012cited by this paper
• Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy

  2011cited by this paper
• Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

  2010cited by this paper
• Targeting the checkpoint kinase Chk1 in cancer therapy

  2010cited by this paper
• The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106

  2010cited by this paper
• Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.

  2010cited by this paper
• Cisplatin-Induced DNA Damage Activates Replication Checkpoint Signaling Components that Differentially Affect Tumor Cell Survival

  2009cited by this paper
• Abstract B248: Characterization and preclinical development of LCI‐1, a selective and potent Chk1 inhibitor in phase 1 clinical trials

  2009cited by this paper
• AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

  2008cited by this paper
• Caffeine markedly sensitizes human mesothelioma cell lines to pemetrexed

  2008cited by this paper
• Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

  2008cited by this paper
• Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1

  2008cited by this paper
• Targeting Checkpoint Kinase 1 in Cancer Therapeutics

  2007cited by this paper
• Pharmacological Abrogation of S-Phase Checkpoint Enhances the Anti-Tumor Activity of Gemcitabine In Vivo

  2007cited by this paper
• Inhibitors of checkpoint kinases: from discovery to the clinic.

  2007cited by this paper
• CHIR-124, a Novel Potent Inhibitor of Chk1, Potentiates the Cytotoxicity of Topoisomerase I Poisons In vitro and In vivo

  2007cited by this paper
• Control of the G2/M transition

  2006cited by this paper
• A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation

  2005cited by this paper
• Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003.

  2005cited by this paper
• Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine.

  2005cited by this paper
• Gemcitabine-Induced Activation of Checkpoint Signaling Pathways That Affect Tumor Cell Survival

  2005cited by this paper
• The Cyclin-Dependent Kinase Inhibitor UCN-01 Plus Cisplatin in Advanced Solid Tumors: A California Cancer Consortium Phase I Pharmacokinetic and Molecular Correlative Trial

  2005cited by this paper
• Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors.

  2005cited by this paper
• Pemetrexed: a multitargeted antifolate.

  2005cited by this paper
• Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints

  2002cited by this paper
• Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first‐line therapy in patients with advanced nonsmall cell lung carcinoma

  2001cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint.

  2000cited by this paper
• Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells.

  1998cited by this paper
• Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25.

  1997cited by this paper
• Impact of schedule on leucovorin potentiation of fluorouracil antitumor activity in dietary folic acid deplete mice.

  1997cited by this paper
• Specific absorbed fractions of energy at various ages from internal photon sources: 6, Newborn

  1987cited by this paper
• Thymidine concentrations in serum and urine of different animal species and man.

  1977cited by this paper

• Revisiting CHK1 and WEE1 kinases as therapeutic targets in cancer.

  2025cites this paper
• Prexasertib exerts a synergistic effect on the antitumor activity of Lenvatinib through ALOX15-mediated ferroptosis in hepatocellular carcinoma.

  2025cites this paper
• Targeting the DNA damage response in cancer

  2024cites this paper
• The thioredoxin system determines CHK1 inhibitor sensitivity via redox-mediated regulation of ribonucleotide reductase activity

  2024cites this paper
• Targeting the DNA Damage Response for Cancer Therapy

  2023cites this paper
• The thioredoxin system determines CHK1 inhibitor sensitivity via redox-mediated regulation of ribonucleotide reductase activity

  2023cites this paper
• Double‐strand DNA break repair: molecular mechanisms and therapeutic targets

  2023cites this paper
• Chk1 Inhibition Ameliorates Alzheimer’s Disease Pathogenesis and Cognitive Dysfunction Through CIP2A/PP2A Signaling

  2022cites this paper
• The cytosolic iron–sulfur cluster assembly (CIA) pathway is required for replication stress tolerance of cancer cells to Chk1 and ATR inhibitors

  2021cites this paper
• Adverse Cerebral Cardiovascular Events Associated With Checkpoint Kinase 1 Inhibitors: A Systemic Review

  2021cites this paper
• CCNE1 Is a Putative Therapeutic Target for ARID1A-Mutated Ovarian Clear Cell Carcinoma

  2021cites this paper
• Chk1 and the Host Cell DNA Damage Response as a Potential Antiviral Target in BK Polyomavirus Infection

  2021cites this paper
• The Challenge of Combining Chemo- and Radiotherapy with Checkpoint Kinase Inhibitors

  2020cites this paper
• GLI1 Inhibitor SRI-38832 Attenuates Chemotherapeutic Resistance by Downregulating NBS1 Transcription in BRAFV600E Colorectal Cancer

  2020cites this paper
• Acquired small cell lung cancer resistance to Chk1 inhibitors involves Wee1 up‐regulation

  2020cites this paper
• Targeting DNA Repair Pathways in Hematological Malignancies

  2020cites this paper
• Checkpoint Kinase 1 Inhibition Enhances Cisplatin Cytotoxicity and Overcomes Cisplatin Resistance in SCLC by Promoting Mitotic Cell Death.

  2019cites this paper
• Chk1 inhibition enhances cisplatin cytotoxicity and overcomes cisplatin resistance in small cell lung cancer by promoting mitotic cell death

  2019cites this paper
• Targeting the cell cycle in head and neck cancer by Chk1 inhibition: a novel concept of bimodal cell death

  2019cites this paper
• Stilbene Compounds Inhibit Tumor Growth by the Induction of Cellular Senescence and the Inhibition of Telomerase Activity

  2019cites this paper
• Targeting CHK1 for Cancer Therapy: Rationale, Progress and Prospects

  2018cites this paper
• Preclinical Profiles and Contexts for CHK1 and CHK2 Inhibitors

  2018cites this paper
• Dose‐finding study of the checkpoint kinase 1 inhibitor, prexasertib, in Japanese patients with advanced solid tumors

  2018cites this paper
• Clinical Development of CHK1 Inhibitors

  2018cites this paper
• Inhibition of CHK1 sensitizes Ewing sarcoma cells to the ribonucleotide reductase inhibitor gemcitabine

  2017cites this paper
• Inhibition of CHK1 sensitizes Ewing sarcoma cells to the ribonucleotide reductase inhibitor gemcitabine.

  2017cites this paper
• ATR/CHK1 inhibitors and cancer therapy.

  2017cites this paper
• A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients

  2017cites this paper
• Directing the use of DDR kinase inhibitors in cancer treatment

  2017cites this paper
• Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.

  2017cites this paper
• Achieving Precision Death with Cell-Cycle Inhibitors that Target DNA Replication and Repair

  2017cites this paper
• Lack of Casein Kinase 1 Delta Promotes Genomic Instability - The Accumulation of DNA Damage and Down-Regulation of Checkpoint Kinase 1

  2017cites this paper
• CHK1 inhibition sensitizes pancreatic cancer cells to gemcitabine via promoting CDK-dependent DNA damage and ribonucleotide reductase downregulation.

  2017cites this paper
• [Impairment of DNA damage response and cancer].

  2017cites this paper
• The cell cycle checkpoint inhibitors in the treatment of leukemias

  2017influential citation
• Selective Kinase Inhibitors in Cancer

  2017cites this paper
• A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer.

  2017cites this paper
• Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.

  2017cites this paper
• The Inhibition of Chk1/Chk2 and Wee-1 Kinases as a Promising Therapy for the Treatment of Adult Acute Lymphoblastic Leukemia

  2016cites this paper
• Etude de nouvelles fonctions de la protéine checkpoint kinase 1 (Chk1) au cours de la différenciation myéloïde normale et leucémique

  2016cites this paper
• DNA Repair Pathways as a Potential Target for Radiosensitization

  2016cites this paper
• ATR-Chk 1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer

  2016cites this paper
• Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer

  2016cites this paper
• DNA repair targeted therapy: The past or future of cancer treatment?

  2016cites this paper
• LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models

  2016cites this paper
• Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors

  2016cites this paper
• Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer.

  2016cites this paper
• APRIN(PDS5B) et PALB2, deux protéines impliquées dans la réparation de l'ADN par recombinaison homologue et l'apparition de cancers

  2016cites this paper
• Novel therapeutic targets on the horizon for lung cancer.

  2016cites this paper
• Trial Watch: Targeting ATM–CHK2 and ATR–CHK1 pathways for anticancer therapy

  2015cites this paper
• Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors

  2015cites this paper
• Targeting lung cancer through inhibition of checkpoint kinases

  2015cites this paper
• An evaluation of the checkpoint kinase inhibitor V158411

  2015cites this paper
• Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells

  2015cites this paper
• The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma

  2015cites this paper
• DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles’ Heel of Cancer

  2015cites this paper
• Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.

  2015cites this paper
• Aven‐mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma

  2015cites this paper
• Causes Replication Catastrophe and Antitumor Effects through CHK 1-Dependent Mechanisms

  2015cites this paper
• LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms

  2015cites this paper
• ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer

  2015cites this paper
• Targeting the Checkpoint to Kill Cancer Cells

  2015cites this paper
• Title : LY 2606368 causes replication catastrophe and anti-tumor effects through CHK 1-dependent mechanisms

  2015cites this paper